Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  An, Yinghong ^a   Guo, Wanjun ^b   Li, Linna ^b   Xu, Chengwang ^b   Yang, Dexuan ^b   Wang, Shanshan ^b   Lu, Yaxin ^c   Zhang, Quan ^c   Zhai, Jiadai ^c   Fan, Hongxia ^c   Qiu, Chuanjiang ^d   Qi, Jie ^d   Chen, Yue ^d   Yuan, Shoujun ^b  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c Collaborative Innovation Center of Chemical Science and Engineering   (China)

^d Accendatech Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIMETHYLAMINOMICHELIOLIDE; MATRIGEL; MICHELIOLIDE DERIVATIVE; PROTEIN BCL 2; UNCLASSIFIED DRUG; SESQUITERPENE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CANCER INHIBITION; CANCER STEM CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG STRUCTURE; FLUORESCENCE ACTIVATED CELL SORTING; FOOD INTAKE; GLIOMA; GLIOMA CELL LINE; HISTOPATHOLOGY; IC50; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MASS SPECTROMETRY; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR GROWTH; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PATHOPHYSIOLOGY; SYNTHESIS; TANDEM MASS SPECTROMETRY; WISTAR RAT;

RATTUS;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CELL LINE; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLOW CYTOMETRY; GLIOMA; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SESQUITERPENES, GUAIANE; TANDEM MASS SPECTROMETRY; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84922699892     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116202     Document Type: Article

References (35)

1. Mrugala MM (2013) Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med 15: 221-230. PMID: 23636139
2. Westphal M, Lamszus K (2011) The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 12: 495-508. doi: 10.1038/nrn3060 PMID: 21811295
3. Sengupta S, Marrinan J, Frishman C, Sampath P (2012) Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol 2012: 831090. doi: 10.1155/2012/831090 PMID: 23133490
4. DeAngelis LM (2001) Brain tumors. N Engl J Med 344: 114-123. PMID: 11150363
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. PMID: 15758009
6. Lefranc F, Brotchi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23: 2411-2422. PMID: 15800333
7. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895
8. Brain and Spinal Cord Tumors in Children (2010) American Cancer Society Atlanta, Ga, USA.
9. National Cancer Institute (2010) FDA Approval for Temozolomide. Available: www.cancer.gov/ cancertopics/druginfo/fda-temozolomide.
10. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, et al. (2011) Greater chemotherapyinduced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13: 324-333. doi: 10.1093/neuonc/noq157 PMID: 21149254
11. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61. PMID: 9189180
12. Wang X, Duan X, Yang G, Zhang X, Deng L, et al. (2011) Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One 6: e18490. doi: 10.1371/journal.pone.0018490 PMID: 21559510
13. Nieto-Sampedro M, Valle-Argos B, Gómez-Nicola D, Fernández-Mayoralas A, Nieto-Díaz M (2011) Inhibitors of glioma growth that reveal the tumour to the immune system. Clin Med Insights Oncol 5:265-314. doi: 10.4137/CMO.S7685 PMID: 22084619
14. Anderson KN, Bejcek BE (2008) Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB. J Pharmacol Sci 106: 318-320. PMID: 18277052
15. Jin P, Madieh S, Augsburger LL (2007) The solution and solid state stability and excipient compatibility of parthenolide in feverfew. AAPS PharmSciTech 8: E105. doi: 10.1208/pt0804105 PMID: 18181526
16. Zhang Q, Lu Y, Ding Y, Zhai J, Ji Q, et al. (2012) Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem 55: 8757-8769. doi: 10.1021/jm301064b PMID: 22985027
17. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412. doi: 10.1371/ journal.pbio.1000412 PMID: 20613859
18. Zhai JD, Li D, Long J, Zhang HL, Lin JP, et al. (2012) Biomimetic semisynthesis of arglabin from parthenolide. J Org Chem 77: 7103-7107. doi: 10.1021/jo300888s PMID: 22849854
19. Chen Y, Zhang Q, Zhai JD, Ma WW, Fan HX, Zhang F (2010) W. C. N. Patent 201,010,153,701.0.
20. von Eckardstein KL, Patt S, Kratzel C, Kiwit JC, Reszka R (2005) Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neurooncol 72: 209-215. PMID: 15937642
21. Guo M, Roman RJ, Fenstermacher JD, Brown SL, Falck JR, et al. (2006) 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N'-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. J Pharmacol Exp Ther 317: 97-108. PMID: 16352703
22. Feng MR (2002) Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab 3: 647-657. PMID: 12369891
23. Abbott NJ (2004) Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol 1:407-416. doi: 10.1016/j.ddtec.2004.11.014 PMID: 24981621
24. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl- XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 95:5724-5729. PMID: 9576951
25. Colpo A, Wilson FH, Nardi V, Hochberg E (2012) Administration of vincristine in a patient with Machado-Joseph disease. Oncology 82:165-167. doi: 10.1159/000336602 PMID: 22433430
26. Tyler B, Wadsworth S, Recinos V, Mehta V, Vellimana A, et al. (2011) Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro Oncol 13: 700-709. doi: 10.1093/neuonc/nor050 PMID: 21727209
27. Li D, Yang K, Li JS, Ke XY, Duan Y, et al. (2012) Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. Int J Nanomedicine 7: 6105-6114. doi: 10.2147/IJN. S38927 PMID: 23269869
28. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281. PMID: 17538086
29. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, et al. (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23: 5314-5322. PMID: 15955899
30. Dell'Agli M, Galli GV, Bosisio E, D'Ambrosio M (2009) Inhibition of NF-kB and metalloproteinase-9 expression and secretion by parthenolide derivatives. Bioorg Med Chem Lett 19: 1858-1860. doi: 10. 1016/j.bmcl.2009.02.080 PMID: 19269818
31. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, et al. (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110: 4427-4435. PMID: 17804695
32. Carlisi D, D'Anneo A, Angileri L, Lauricella M, Emanuele S, et al. (2011) Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 226:1632-1641. doi: 10.1002/jcp.22494 PMID: 21413021
33. Sun J, Zhang C, Bao YL, Wu Y, Chen ZL, et al. (2014) Parthenolide-induced apoptosis, autophagy and suppression of proliferation in HepG2 cells. Asian Pac J Cancer Prev 15: 4897-4902. PMID: 24998560
34. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, et al. (1999) BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67: 763-768. PMID: 10567494
35. Murphy S, Davey RA, Gu XQ, Haywood MC, McCann LA, et al. (2007) Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model. J Neurooncol 85: 181-189. PMID: 17534579